More relevant to the work reported here, we have also shown that SMM-189 normalizes depression and contextual fear and diminishes conditioned fear after focal cranial blast.17 Further, SMM-189, the CB2 inverse agonist SR144528, and raloxifene yield a similar rescue of the contrast-sensitivity deficit produced by focal cranial blast, consistent with the idea that raloxifene rescue of visual deficits is attributable to effects on CB2 receptors.17,20,,23. The gene discussed is CNR2; the disease is depressive disorder.